| Abstract | Cilj istraživanja Cilj je ovog istraživanja usporediti dijagnostički značaj konvencionalnog biljega mioglobina i novijeg biljega, srčanog proteina koji veže masne kiseline u AKS. Nacrt studije Nacrt studije čini presječno istraživanje (prospektivno istraživanje parova). Ispitanici i metode Ispitanici su (N = 94) bili podijeljeni u tri skupine: pacijenti s NSTEMI AIM-om (N = 37), pacijenti s NAP-om (N = 15) te kontrolni ispitanici (N = 42). Ispitanicima je uzeta anamneza te im je napravljen EKG. Koncentracije Tnl-a izmjerene su kemiluminiscentnom imunoanalizom baziranoj na LOCI tehnologiji, a koncentracije mioglobina heterogenom imunoanalizom na Dimension EXL s LM analizatoru (Siemens Healthcare Diagnostics Inc., Newark, USA). Mjerenje H-FABP-a je provedeno na Beckman Coulter AU 680 analizatoru (Beckman Coulter Inc., Brea, USA) imunoturbidimetrijskom metodom. Rezultati su obrađeni statističkim programom MedCalc (MedCalc Software, Mariakerke, Belgium). Rezultati Vrijednosti medijana za H-FABP i mioglobin bile su više kod pacijenata s NSTEMI AIM-om u odnosu na pacijente s NAP-om i kontrolne ispitanike; H-FABP: 8,66 vs. 5,41 vs. 5,66 (P = 0,005); mioglobin: 57,8 vs. 48,8 vs. 49,8 (P = 0,047). H-FABP je pokazao bolju specifičnost (59,5 % vs. 50,0 %) i jednaku osjetljivost (78,4 %) u usporedbi s mioglobinom u dijagnostici NSTEMI AIM-a. Zaključak Vrijednosti koncentracija H-FABP-a razlikuju se među ispitivanim skupinama te su kod ispitanika koji su razvili NSTEMI AIM višlje. H-FABP se pokazao ranijim biljegom AIM-a u odnosu na mioglobin, pokazavši jednaku dijagnostičku osjetljivost, ali veću specifičnost od mioglobina pri optimalnim graničnim vrijednostima u dijagnostici NSTEMI AIM-a te se može smatrati obećavajućim srčanim biomarkerom uz TnI. |
| Abstract (english) | Objectives The aim of this study is to compare the diagnostic significance of the conventional myoglobin marker and the new marker, a heart protein that binds fatty acids to ACS. Study Design The study is designed as a cross-sectional study (prospective case-control study). Participants and Methods Participants (N=94) were divided into three groups: patients with NSTEMI AMI (N=37), patients with UAP (N=15) and control group (N=42). Anamnesis was taken from all of the patients and an ECG was made. TnI concentration was measured by chemiluminescent immunoassay based on LOCI technology, and myoglobin concentration by heterogeneous immunoassay on Dimension EXL with LM analyser (Siemens Healthcare Diagnostics Inc., Newark, USA). H-FABP measuring was done on the Beckman Coulter AU 680 analyser (Beckman Coulter Inc., Brea, USA) by immunoturbidimetric method. The results were processed in statistical program MedCalc (MedCalc Software, Mariakerke, Belgium). Results Median values for H-FABP and myoglobin were higher in patients with NSTEMI AMI compared to patients with UAP and control subjects; H-FABP: 8.66 vs. 5.41 vs. 5.66 (P=0.005); myoglobin: 57.8 vs. 48.8 vs. 49.8 (P=0.047). H-FABP indicated better specificity (59.5% vs. 50.0%) and equal sensitivity (78.4%) compared to myoglobin in NSTEMI AMI diagnosis. Conclusion The concentration values of H-FABP differ between the studied groups, and in those who developed NSTEMI AMI they are higher. H-FABP proved as earlier AMI marker compared to myoglobin, showing the same diagnostic sensitivity, but greater specificity than myoglobin at optimal limit values in NSTEMI AMI diagnosis and may be considered a promising cardiac biomarker with TnI. |
